MDACC Study No:2009-0619 ( NCT No: NCT00946647)
Title:A phase Ib/IIb, open-label, multi-center study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza®) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML)
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Azacitidine; Panobinostat
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of panobinostat that can be given in combination with Vidaza® (azacitidine) to
patients with MDS, CMML, or AML. The safety of this drug combination will also
be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:Azacitidine
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:NA
Supported By:Novartis Pharmaceuticals
Return Visit:Cycle 1: Days 1-10, then every 2-4 days (Days 12, 15, 17, 19, 22, 24, and 28,
possibly Days 35 and 42 as well)
Cycle 2 and beyond: weekly
Home Care:NA

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults